Study Information
Status: Active, Recruiting
Study Details
View study details on clinicaltrials.gov.
Locations
San Francisco
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) Versus Investigator's Choice (IC) Chemotherapy in Women With Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)
Location: CPMC (San Francisco)
Please contact: ClinicalResearch@sutterhealth.org about study GOG 3086/SUTRO STRO-002-GM3